IPN Ipsen SA

Ipsen - September 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital

Ipsen - September 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital

Monthly information relative to the total number of voting rights

and shares composing the share capital

(in accordance with Article L.233-8 II of the French Commercial Code and

Article 223-16 of the General Regulation of the Autorité des Marchés Financiers)

Market: Euronext Paris

ISIN Code: FR 0010259150

LEI: 549300M6SGDPB4Z94P11

DateTotal number of shares composing the share capitalTotal number of voting rights (1)
30 September 202483,814,526Gross total* of voting rights: 132,140,937
Net total** of voting rights: 131,040,789

(1) Existence of a statutory clause imposing an obligation to declare threshold crossing complementary to the one relative to the legal thresholds (Article 10).

* Gross total = total number of voting rights attached to the total number of shares, including the number of shares which benefit of double voting rights and the number of treasury shares. The « Gross total » is used as a basis for the calculation of threshold crossings.

** Net total = total number of voting rights attached to the total number of shares – shares without voting rights.



Attachment



EN
09/10/2024

Underlying

IPNIpsen SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ipsen SA

 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen - September 2024 - Monthly information relative to the total num...

Ipsen - September 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulation of the Autorité des Marchés Financiers) Market: Euronext Paris ISIN Code: FR 0010259150LEI: 549300M6SGDPB4Z94P11 DateTotal number of shares composing the share capitalTotal number of voting rights (1)30 September 202483,814,526Gross total* of ...

October 9, 2024 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen - Septembre 2024 - Information mensuelle relative au nombre tota...

Ipsen - Septembre 2024 - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social Information mensuelle relative au nombre total des droits de voteet d’actions composant le capital social (conformément à l’article L.233-8 II du Code de commerceet à l’article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) Place de cotation : Euronext Paris Code ISIN : FR 0010259150LEI : 549300M6SGDPB4Z94P11 Date Nombre total d’actions composant le capital socialNombre total de droits de vote (1)30 septembre 202483 814 526Total brut* des d...

October 9, 2024 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen’s Kayfanda® (odevixibat) approved in European Union for cholesta...

Ipsen’s Kayfanda® (odevixibat) approved in European Union for cholestatic pruritus in Alagille Syndrome, a rare liver disease                                                                  Kayfanda® (odevixibat) approved as new treatment choice for cholestatic pruritus in children from six months with the rare liver condition, Alagille Syndrome E.U. marketing authorization for Kayfanda based on data from ASSERT the only Phase III trial completed in patients with Alagille SyndromeKayfanda approval for use in the E.U. further expands Ipsen’s rare cholestatic liver disease portfolio ...

September 23, 2024 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

Le médicament Kayfanda® (odévixibat) d’Ipsen est approuvé dans l’Union...

Le médicament Kayfanda® (odévixibat) d’Ipsen est approuvé dans l’Union européenne pour le prurit cholestatique lié au syndrome d’Alagille, une maladie hépatique rare                                                                          Kayfanda® (odévixibat) a été approuvé comme nouvelle option thérapeutique pour le prurit cholestatique chez l’enfant de six mois ou plus atteint du syndrome d’Alagille, une maladie rare du foie. L’autorisation de mise sur le marché accordée dans l’UE pour Kayfanda se base sur les données d’ASSERT, le seul essai de Phase III mené à son terme chez des pa...

September 23, 2024 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen’s Iqirvo® (elafibranor) approved in the European Union as first ...

Ipsen’s Iqirvo® (elafibranor) approved in the European Union as first new treatment for primary biliary cholangitis in nearly a decade European Commission grants conditional marketing authorization for Iqirvo® (elafibranor), first-in-class new treatment for primary biliary cholangitis (PBC), a rare liver diseaseApproval follows positive CHMP opinion based on ELATIVE phase III trial data, which demonstrated significant efficacy over placebo and was well-tolerated with an acceptable safety profile This new European approval reinforces Ipsen’s commitment to advancing medical innovations to tre...

September 20, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch